Equine macrophage identification with an antibody (Ki-M6) to human CD68 and a new monoclonal antibody (JB10).

The study focuses on developing and comparing monoclonal antibodies for the identification of macrophages in horses, an area which has been rarely explored previously. Two monoclonal antibodies, Ki-M6 and a newly introduced one, JB10, were compared in their ability to stain and recognize equine macrophages in various equine tissues.

Experiment Procedure

• The study investigated the immobilization staining of several equine tissues (including lymphoid tissue, lung, liver, small intestine, skin, and blood leucocytes) by a monoclonal antibody, Ki-M6, which is known for detecting CD68 in human macrophages and dendritic cells.
• The results obtained from Ki-M6 staining were compared with the staining produced by a newly developed anti-equine monoclonal antibody, JB10.
• In addition, the staining by these antibodies was compared with separation produced by two previously described anti-equine macrophage monoclonal antibodies, CZ2.2 and CZ3.3.
• Flow cytometry was also performed on the leucocytes in peripheral blood to contrast the staining patterns of each antibody.

Experiment Findings

• The study demonstrated that the Ki-M6 monoclonal antibody could successfully identify equine macrophages.
• The macrophages identified by Ki-M6 displayed a different distribution pattern than those identified by the older anti-equine macrophage antibodies CZ2.2 and CZ3.3.
• The new antibody, JB10, showed the capability to identify equine macrophages in a manner similar to Ki-M6. Additionally, it bound specifically to polymorphonuclear leucocytes.
• The staining of JB10 differed from both CZ2.2 and CVS19 (a monoclonal antibody itself), suggesting that JB10 identifies a different molecule on the equine macrophages.

Significance of the Study

• The study adds valuable additional monoclonal antibodies (Ki-M6 and JB10) to the limited pool useful for identifying characteristic populations of macrophages in equine immune responses and pathology.
• Furthermore, the Ki-M6 antibody may allow for a detailed analysis of the structure, distribution, and function of the CD68 molecule in horses, aiding our understanding of equine immunology and potentially contributing to the development of targeted treatments or prevention strategies for equine diseases.